Endostar®:Recombinant Human Endostatin Injection

Endostar®:Recombinant Human Endostatin Injection

Indications:

Used for primary and re-treated therapies for non-small cell lung cancer of stage III/IV.

It is the first listed class I anti-tumor drug in the world, with patents from China and the United States. In addition, it has won the second prize of National Technological Invention Award and China Patent Gold Award, and has been listed in the National Medical Insurance Catalog since 2017.